Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 7Unknown 3Terminated 2Recruiting 2

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Breast 1

Conditions

Colorectal Neoplasms 61Stomach Neoplasms 27Rectal Neoplasms 20Colonic Neoplasms 19Small Cell Lung Carcinoma 12Neoplasm Metastasis 11Pancreatic Neoplasms 10Locally Advanced Rectal Cancer 5Colorectal Cancer Metastatic 5Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Biliary Tract Neoplasms 4Recurrence 3Liver Neoplasms 3Glioblastoma 3Gastrointestinal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Solid Tumors 2Sarcoma 2Lung Neoplasms 2Glioma 2Gallbladder Neoplasms 2Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction 2Advanced Colorectal Cancer 2mCRC 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytopenia 1Second Line Treatment of Gastric Cancer 1

Interventions

Cyclophosphamide 17fludarabine 13Dexamethasone 12Cisplatin 11Rituximab 10Gemcitabine 9Paclitaxel 7Lenalidomide 7Decitabine 7Cytarabine 7Bendamustine Hydrochloride 7fludarabine phosphate 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Etoposide 6Carboplatin 6Bortezomib 6Radiotherapy 5Injections 5Azacitidine 5camrelizumab 4apatinib 4Valproic Acid 4Thalidomide 4Procarbazine 4Oxaliplatin 4Drug Therapy 4Antilymphocyte Serum 4tislelizumab 3pomalidomide 3liposomal doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Recurrence × Irinotecan × Clear all
NCT03613753 2020-02-05

Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer

Guizhou Medical University

Phase 2 Unknown
72 enrolled
Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT02030678 2018-09-05

A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer

Liaoning Cancer Hospital & Institute

Phase 2 Unknown
124 enrolled
Breast

Breast Neoplasms, Recurrence

NCT01380275 2014-09-25

Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.

National Cancer Center, Korea

Phase 2 Unknown
35 enrolled
Sarcoma

Recurrence, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡